Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis

Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Gluc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiciński, Michał, Górski, Karol, Wódkiewicz, Eryk, Walczak, Maciej, Nowaczewska, Magdalena, Malinowski, Bartosz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177465/
https://www.ncbi.nlm.nih.gov/pubmed/32218354
http://dx.doi.org/10.3390/ijms21072275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177465/
https://www.ncbi.nlm.nih.gov/pubmed/32218354
http://dx.doi.org/10.3390/ijms21072275

Ejemplares similares